Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

IDO1/TDO2 inhibitor DN1406131

An inhibitor of both the enzymes indoleamine 2,3-dioxygenase 1 (IDO1; IDO-1) and tryptophan 2,3-dioxygenase 2 (TDO2; TDO-2), with potential immunomodulating and antineoplastic activities. Upon administration, IDO1/TDO2 inhibitor DN1406131 targets, binds to and inhibits both IDO1 and TDO2, which catalyze the first and rate-limiting step in the production of the immunosuppressive transcription factor aryl hydrocarbon receptor (AhR) ligand kynurenine (KYN). This inhibits the IDO1/TDO2-KYN-AhR pathway. Abrogation of AhR activation prevents the activation of immune-tolerant dendritic cells (DCs) and regulatory T cells (Tregs) in the tumor microenvironment (TME). This may restore the immune response against tumor cells in which IDO1 and/or TDO2 are overexpressed. The IDO1/TDO2-KYN-AhR pathway is overexpressed in a variety of tumor cell types, plays a key role in immunosuppression and its expression is correlated with poor prognosis.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:indoleamine 2,3-dioxygenase 1/tryptophan 2,3-dioxygenase 2 inhibitor DN1406131
Code name:DN 1406131
DN-1406131
DN131
DN1406131
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search